The complex deal structure will create a new Irish holding company, which will own both Endo and Paladin, to take advantage of Ireland's low tax rates. ^ 'Endo buys Canada's Paladin to counter sliding sales'.^ 'Endo Health to Buy Specialty Drug Maker for $1.6 Billion'.'Endo Health to Buy Paladin Labs for $1.6 Billion'. Endo met that threshold by buying Paladin Labs, a Canadian drug manufacturer, for $1.6 billion in a deal that was finalized Feb.

The company was able to legally reincorporate in Ireland only after completing a deal to buy a foreign-based company using at least 20 percent of its own stock. 'Endo re-incorporates in Ireland to save millions in taxes' (Blog post).

^ Houlder, Vanessa Boland, Vincent Politi, James (29 April 2014).

In 2021, New York Attorney General Letitia James filed a lawsuit against Endo and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. It was the first time that the FDA had 'taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.' Opana has been linked to outbreaks of HIV, hepatitis C and serious blood disorders. Food and Drug Administration (FDA) released a press statement in which it announced that it requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. Opioids Įndo is one of the companies named in lawsuits by the states of Ohio, Missouri and Mississippi as responsible for the US opioid epidemic. On AugEndo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. In 2022, Endo's stock fell below $1 as the company faced restructuring of its $8 billion of debt. However, Teva prevailed in this acquisition with a substantially higher bid. In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. In 2018, Endo settled over 1,200 lawsuits related to its testosterone replacement therapy, Testim, and its undisclosed side effects. In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion. In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion along with its testosterone replacement therapy products. they could afford to pay more to acquire U.S. In July 2015, The Wall Street Journal noted Endo was using Ireland's lower tax rate to acquire U.S.–based life sciences firms and relocate them to Ireland's tax regime (i.e. Įndo used the 2013 acquisition of Paladin Labs, and Canadian tax laws, to execute a corporate tax inversion to Ireland.

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets. The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel. In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology. We look forward to the opportunities ahead for our combined generics business.See also: Corporation tax in the Republic of Ireland § Corporate tax inversionsĮndo was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon. 'I would like to take the opportunity to thank the leadership team and the hard-working employees at Qualitest for continuing to drive the business forward and deliver year-over-year double-digit growth during this period of transition. 'We are also pleased to welcome Paul Campanelli, former CEO of Par Pharmaceutical, as group president, Par Pharmaceutical to the Endo executive leadership team and are excited about his anticipated contributions to the organisation. Par former CEO Paul Campanelli is joining Endo’s executive leadership team as the new business unit’s group president.Įndo president and CEO Rajiv De Silva said: 'We are pleased to announce the completion of this transformational acquisition that has strategically expanded our product portfolio, R&D pipeline, manufacturing and technology capacity and generics expertise for the benefit of patients, customers and shareholders. 'The purchase price for Par consisted of 18 million shares of Endo equity and $6.5bn in cash.'

Endo pharma slalom